Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China.
Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):94S-103S. doi: 10.1177/1076029618790696. Epub 2018 Aug 13.
Inherited thrombocytopenia is a group of hereditary diseases with a reduction in platelet count as the main clinical manifestation. Clinically, there is an urgent need for a convenient and rapid diagnosis method. We introduced a high-throughput, next-generation sequencing (NGS) platform into the routine diagnosis of patients with unexplained thrombocytopenia and analyzed the gene sequencing results to evaluate the value of NGS technology in the screening and diagnosis of inherited thrombocytopenia. From a cohort of 112 patients with thrombocytopenia, we screened 43 patients with hereditary features. For the blood samples of these 43 patients, a gene sequencing platform for hemorrhagic and thrombotic diseases comprising 89 genes was used to perform gene detection using NGS technology. When we combined the screening results with clinical features and other findings, 15 (34.9%) of 43patients were diagnosed with inherited thrombocytopenia. In addition, 19 pathogenic variants, including 8 previously unreported variants, were identified in these patients. Through the use of this detection platform, we expect to establish a more effective diagnostic approach to such disorders.
遗传性血小板减少症是一组以血小板计数减少为主要临床表现的遗传性疾病。临床上迫切需要一种方便、快速的诊断方法。我们将高通量、下一代测序(NGS)平台引入到不明原因血小板减少症患者的常规诊断中,并分析基因测序结果,以评估 NGS 技术在遗传性血小板减少症筛查和诊断中的价值。在一组 112 例血小板减少症患者中,我们筛选出 43 例具有遗传性特征的患者。对于这 43 名患者的血液样本,我们使用包含 89 个基因的出血和血栓形成疾病基因测序平台,采用 NGS 技术进行基因检测。当我们将筛查结果与临床特征和其他发现相结合时,43 名患者中有 15 名(34.9%)被诊断为遗传性血小板减少症。此外,在这些患者中还鉴定出 19 种致病性变异,包括 8 种以前未报道过的变异。通过使用这种检测平台,我们希望建立一种更有效的诊断方法来诊断这些疾病。